Form 4: Sangamo Therapeutics Insider Tax Withholding Transaction

Gregory D. Davis, Head of Research & Technology at Sangamo Therapeutics, reported a mandatory tax withholding transaction involving 1,630 shares.

Summary

• Gregory D. Davis, Head of Research & Technology at Sangamo Therapeutics, Inc. (SGMO), disposed of 1,630 shares of common stock.
• The transaction occurred on May 25, 2026, at a price of $0.1743 per share.
• The disposal was a mandatory tax withholding related to the vesting of Restricted Stock Units (RSUs).
• Following this transaction, the reporting person holds 113,654 shares of common stock.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral administrative event, as the share disposal was mandatory for tax purposes and does not indicate a change in management sentiment regarding the company's outlook.

Positives

• The transaction was non-discretionary and performed solely for tax compliance purposes.
• The reporting person maintains a significant equity stake of 113,654 shares.

Negatives

• The transaction reflects a reduction in the reporting person's direct share ownership.

Risks

• Continued reliance on equity-based compensation subject to vesting schedules.
• Market price volatility affecting the value of remaining RSU grants.

Future Outlook

The filing notes that 32,633 shares from the February 25, 2025 RSU grant remain to vest in 7 successive equal quarterly installments, subject to continuous service.

Industry Context

StockSavvy.ai notes that mandatory tax withholding filings are routine administrative events in the biotechnology sector, where equity compensation is a standard component of executive remuneration packages.

Comparison to Industry Standards

• The use of 'sell-to-cover' transactions for tax obligations is a standard practice among publicly traded biotech firms to manage executive tax liabilities.
• The reporting structure aligns with standard SEC Section 16(a) compliance requirements for corporate officers.

Stakeholder Impact

• Minimal impact on shareholders as the transaction was a non-discretionary tax withholding event.

Next Steps

• Continued vesting of remaining RSU grants in 7 successive equal quarterly installments.

Key Dates

Keywords

Sangamo Therapeutics, SGMO, Form 4, Insider Trading, Tax Withholding, Biotech